Russia (bbabo.net), - The triple vaccination regimen with EpiVacCoron-N is intended primarily for immunocompromised patients. This was reported to journalists at the Vector center of Rospotrebnadzor.
At the same time, the developers assured that the two-fold scheme also gives an immune response. "The use of the EpiVacCorona-N vaccine according to the three-dose regimen is intended primarily for patients with immune system characteristics, weakened immunity against the background of chronic diseases," the report says (quoted by TASS).
Earlier, Vector stated that EpiVacCorona-N is safe and does not cause allergic reactions. According to studies, six months after the start of the vaccination course, antibodies appeared in 98% of participants who received three doses of the vaccine. In the group of patients who received two doses of the vaccine, this figure was 81%.
"EpiVakKorona-N" is the second development of the Novosibirsk Scientific Center for vaccination against СOVID-19. Like the first Vector vaccine, EpiVacCoron, the new drug was created on the basis of peptide antigens. The new vaccine is available in the form of a suspension for intramuscular injection.
bbabo.Net